65 related articles for article (PubMed ID: 22399593)
1. Cetuximab sensitivity associated with oxaliplatin resistance in colorectal cancer.
Ekblad L; Johnsson A
Anticancer Res; 2012 Mar; 32(3):783-6. PubMed ID: 22399593
[TBL] [Abstract][Full Text] [Related]
2. In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR.
Balin-Gauthier D; Delord JP; Rochaix P; Mallard V; Thomas F; Hennebelle I; Bugat R; Canal P; Allal C
Cancer Chemother Pharmacol; 2006 Jun; 57(6):709-18. PubMed ID: 16320055
[TBL] [Abstract][Full Text] [Related]
3. Tumors established with cell lines selected for oxaliplatin resistance respond to oxaliplatin if combined with cetuximab.
Prewett M; Deevi DS; Bassi R; Fan F; Ellis LM; Hicklin DJ; Tonra JR
Clin Cancer Res; 2007 Dec; 13(24):7432-40. PubMed ID: 18094427
[TBL] [Abstract][Full Text] [Related]
4. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
5. Chemotherapy of metastatic colorectal cancer.
Prescrire Int; 2010 Oct; 19(109):219-24. PubMed ID: 21180382
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of cetuximab in combination with fluorouracil, leucovorin, and oxaliplatin in the first-line treatment of metastatic colorectal cancer.
Tabernero J; Van Cutsem E; Díaz-Rubio E; Cervantes A; Humblet Y; André T; Van Laethem JL; Soulié P; Casado E; Verslype C; Valera JS; Tortora G; Ciardiello F; Kisker O; de Gramont A
J Clin Oncol; 2007 Nov; 25(33):5225-32. PubMed ID: 18024868
[TBL] [Abstract][Full Text] [Related]
7. Assessment of cytotoxicity, apoptosis and DNA damages in Colo320 colorectal cancer cells selected for oxaliplatin resistance.
Virag P; Brie I; Fischer-Fodor E; Perde-Schrepler M; Tatomir C; Balacescu O; Irimie A; Postescu ID
Cell Biochem Funct; 2011 Jul; 29(5):351-5. PubMed ID: 21491469
[TBL] [Abstract][Full Text] [Related]
8. Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines.
Dahan L; Sadok A; Formento JL; Seitz JF; Kovacic H
Br J Pharmacol; 2009 Sep; 158(2):610-20. PubMed ID: 19732064
[TBL] [Abstract][Full Text] [Related]
9. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines.
Yang AD; Fan F; Camp ER; van Buren G; Liu W; Somcio R; Gray MJ; Cheng H; Hoff PM; Ellis LM
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4147-53. PubMed ID: 16857785
[TBL] [Abstract][Full Text] [Related]
10. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells.
Ekblad L; Kjellström J; Johnsson A
Anticancer Drugs; 2010 Jun; 21(5):523-31. PubMed ID: 20168208
[TBL] [Abstract][Full Text] [Related]
11. Cetuximab plus oxaliplatin-based chemotherapy in the treatment of colorectal cancer.
Moosmann N; Heinemann V
Expert Rev Anticancer Ther; 2008 Mar; 8(3):319-29. PubMed ID: 18366281
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab-oxaliplatin-liposomes for epidermal growth factor receptor targeted chemotherapy of colorectal cancer.
Zalba S; Contreras AM; Haeri A; Ten Hagen TL; Navarro I; Koning G; Garrido MJ
J Control Release; 2015 Jul; 210():26-38. PubMed ID: 25998052
[TBL] [Abstract][Full Text] [Related]
13. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in cervical cancer: implications for Cetuximab-mediated therapy in recurrent/metastatic disease.
Bellone S; Frera G; Landolfi G; Romani C; Bandiera E; Tognon G; Roman JJ; Burnett AF; Pecorelli S; Santin AD
Gynecol Oncol; 2007 Sep; 106(3):513-20. PubMed ID: 17540437
[TBL] [Abstract][Full Text] [Related]
14. Toll-like receptor 9 agonist IMO cooperates with cetuximab in K-ras mutant colorectal and pancreatic cancers.
Rosa R; Melisi D; Damiano V; Bianco R; Garofalo S; Gelardi T; Agrawal S; Di Nicolantonio F; Scarpa A; Bardelli A; Tortora G
Clin Cancer Res; 2011 Oct; 17(20):6531-41. PubMed ID: 21890455
[TBL] [Abstract][Full Text] [Related]
15. Cetuximab-mediated cellular cytotoxicity is inhibited by HLA-E membrane expression in colon cancer cells.
Levy EM; Sycz G; Arriaga JM; Barrio MM; von Euw EM; Morales SB; González M; Mordoh J; Bianchini M
Innate Immun; 2009 Apr; 15(2):91-100. PubMed ID: 19318419
[TBL] [Abstract][Full Text] [Related]
16. Cetuximab: new drug. Metastatic colorectal cancer: an inappropriate evaluation.
Prescrire Int; 2005 Dec; 14(80):215-7. PubMed ID: 16400742
[TBL] [Abstract][Full Text] [Related]
17. Epidermal growth factor receptor (EGFR) ubiquitination as a mechanism of acquired resistance escaping treatment by the anti-EGFR monoclonal antibody cetuximab.
Lu Y; Li X; Liang K; Luwor R; Siddik ZH; Mills GB; Mendelsohn J; Fan Z
Cancer Res; 2007 Sep; 67(17):8240-7. PubMed ID: 17804738
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines.
Noordhuis P; Laan AC; van de Born K; Losekoot N; Kathmann I; Peters GJ
Biochem Pharmacol; 2008 Jul; 76(1):53-61. PubMed ID: 18508032
[TBL] [Abstract][Full Text] [Related]
19. Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells.
Stordal BK; Davey MW; Davey RA
Cancer Chemother Pharmacol; 2006 Aug; 58(2):256-65. PubMed ID: 16283310
[TBL] [Abstract][Full Text] [Related]
20. Oxaliplatin resistance induced by ERCC1 up-regulation is abrogated by siRNA-mediated gene silencing in human colorectal cancer cells.
Seetharam RN; Sood A; Basu-Mallick A; Augenlicht LH; Mariadason JM; Goel S
Anticancer Res; 2010 Jul; 30(7):2531-8. PubMed ID: 20682979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]